Literature DB >> 1637878

Prevention of viridans-group streptococcal septicemia in oncohematologic patients: a controlled comparative study on the effect of penicillin G and cotrimoxazole.

H F Guiot1, J W van der Meer, P J van den Broek, R Willemze, R van Furth.   

Abstract

In a controlled randomized study among 48 patients undergoing 75 courses of aggressive antileukemic therapy, it was shown that cotrimoxazole was less effective than penicillin G in preventing septicemia due to viridans streptococci. Both antibiotics were given intravenously. During 35 episodes of chemotherapy in the group of patients on penicillin G only, one patient developed a streptococcal bacteremia; this contrasted with bacteremia and septicemia in seven patients during 40 episodes in the group on cotrimoxazole. In three of these seven patients, septicemia was associated with respiratory failure and it was the cause of death in one. Both aerobic gram-negative rods and streptococci which caused infection despite cotrimoxazole prophylaxis were resistant to cotrimoxazole. Side effects such as hypersensitivity and favorable or unfavorable interaction with the oral selective decontamination regimen were similar for the two drugs, with the exception of colonization with Candida spp, which occurred more often in patients on cotrimoxazole than in patients on penicillin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1637878     DOI: 10.1007/bf01695467

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  30 in total

1.  Antimicrobial susceptibilities of Streptococcus species that cause septicemia in neutropenic patients.

Authors:  M Venditti; P Baiocchi; C Santini; C Brandimarte; P Serra; G Gentile; C Girmenia; P Martino
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

2.  Streptococcal sepsis in bone marrow transplant patients.

Authors:  J Henslee; B Bostrom; D Weisdorf; N Ramsay; P McGlave; J Kersey
Journal:  Lancet       Date:  1984-02-18       Impact factor: 79.321

3.  Intermediate and high dose Ara-C and m-AMSA for remission induction and consolidation treatment of patients with acute myeloid leukemia: an EORTC Leukemia Cooperative Group phase II study.

Authors:  R Willemze; U Jager; U Jehn; P Stryckmans; J Bury; S Suciu; G Solbu; R Zittoun; J Burghouts; B Löwenberg
Journal:  Eur J Cancer Clin Oncol       Date:  1988-11

4.  Incidence of trimethoprim-sulfamethoxazole-resistant enterobacteriaceae among transplant recipients.

Authors:  C L Wells; R P Podzorski; P K Peterson; N K Ramsay; R L Simmons; F S Rhame
Journal:  J Infect Dis       Date:  1984-11       Impact factor: 5.226

5.  Alpha-hemolytic streptococci: clinical significance in the cancer patient.

Authors:  P A Pizzo; S Ladisch; F G Witebsky
Journal:  Med Pediatr Oncol       Date:  1978

6.  Septicaemia caused by viridans streptococci in neutropenic patients with leukaemia.

Authors:  J Cohen; J P Donnelly; A M Worsley; D Catovsky; J M Goldman; D A Galton
Journal:  Lancet       Date:  1983 Dec 24-31       Impact factor: 79.321

7.  Prevention of infection by trimethoprim-sulfamethoxazole plus amphotericin B in patients with acute nonlymphocytic leukaemia.

Authors:  A W Dekker; M Rozenberg-Arska; J J Sixma; J Verhoef
Journal:  Ann Intern Med       Date:  1981-11       Impact factor: 25.391

8.  Septicemia in pediatric oncology patients: the significance of viridans streptococcal infections.

Authors:  S J Weisman; F J Scoopo; G M Johnson; A J Altman; J J Quinn
Journal:  J Clin Oncol       Date:  1990-03       Impact factor: 44.544

9.  Selective antimicrobial modulation of the intestinal microbial flora for infection prevention in patients with hematologic malignancies. Evaluation of clinical efficacy and the value of surveillance cultures.

Authors:  H F Guiot; A V Helmig-Schurter; J W van der Meer; R van Furth
Journal:  Scand J Infect Dis       Date:  1986

10.  Short-term intensive treatment (V.A.A.P.) of adult acute lymphoblastic leukemia and lymphoblastic lymphoma.

Authors:  R Willemze; W G Peters; L P Colly
Journal:  Eur J Haematol       Date:  1988-11       Impact factor: 2.997

View more
  6 in total

Review 1.  It's not easy being green: the viridans group streptococci, with a focus on pediatric clinical manifestations.

Authors:  Christopher D Doern; Carey-Ann D Burnham
Journal:  J Clin Microbiol       Date:  2010-09-01       Impact factor: 5.948

2.  Randomized trial of the addition of gram-positive prophylaxis to standard antimicrobial prophylaxis for patients undergoing autologous bone marrow transplantation.

Authors:  E R Broun; J L Wheat; P H Kneebone; K Sundblad; R A Hromas; G Tricot
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

Review 3.  Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy.

Authors:  Anat Gafter-Gvili; Abigail Fraser; Mical Paul; Liat Vidal; Theresa A Lawrie; Marianne D van de Wetering; Leontien C M Kremer; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2012-01-18

4.  Evaluation of penicillin G in the prevention of streptococcal septicaemia in patients with acute myeloid leukaemia undergoing cytotoxic chemotherapy.

Authors:  P de Jong; M de Jong; E Kuijper; J van der Lelie
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-10       Impact factor: 3.267

5.  A randomized trial of roxithromycin in patients with acute leukemia and bone marrow transplant recipients receiving fluoroquinolone prophylaxis.

Authors:  W V Kern; B Hay; P Kern; R Marre; R Arnold
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

6.  Prevalence of penicillin-resistant viridans streptococci in healthy children and in patients with malignant haematological disorders.

Authors:  H F Guiot; L J Corel; J M Vossen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-08       Impact factor: 3.267

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.